Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Refine Results
Minimal Residual Disease Finding the Right Test for the New Definition of...

Measurement of Residual Disease for improved oncology trial outcomes

NGS methods capturing splice variants: Picking the right tool to detect...

Presentation from Precision: Lung Cancer Summit, July 2017

Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials

Genomic technologies that empower and enhance immuno-oncology trials

Fighting Cancer Biomarkers for Immuno-Oncology Clinical Trials

Using anatomic pathology for biomarker development in clinical trials can help predict and assess...

Technical Innovations Advance Gene Expression Profiling

Small-Volume RNA-seq and Improved SMART-Seq® v4 Workflow

The End to End Importance of Selecting the Right Biomarker in Cancer...

A critical component in the fight against cancer and optimizing treatment outcomes for patients

Best Practices for Integrating Biomarkers across the Drug Development...

A roadmap for a successful biomarker strategy

Minimal Residual Disease Detection: Key Considerations for Clinical...

What you should know for your clinical development program

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet...

Q2 Solutions Corporate Brochure

Learn who we are, what we do, and how we impact customers through the lens of our vision, mission...

Designing AML Panel for Clinical Testing

Presentation from PMWC - Duke University, May 2017